The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study
Open accessAbstract
OBJECTIVES: To investigate the cardiovascular safety of non-steroidal anti-inflammatory drugs (NSAIDs) and estimate the risk of hospital admission for heart failure with use of individual NSAIDs. DESIGN: Nested case-control study. SETTING: Five population based healthcare databases from four European countries (the Netherlands, Italy, Germany, and the United Kingdom). PARTICIPANTS: Adult individuals (age ≥18 years) who started NSAID treatment in 2000-10. Overall, 92 163 hospital admissions for heart failure were identified and matched with 8 246 403 controls (matched via risk set sampling according to age, sex, year of cohort entry). MAIN OUTCOME MEASURE: Association between risk of hospital admission for heart failure and use of 27 individual NSAIDs, including 23 traditional NSAIDs and four selective COX 2 inhibitors. Associations were assessed by multivariable conditional logistic regression models. The dose-response relation between NSAID use and heart failure risk was also assessed. RESULTS: Current use of any NSAID (use in preceding 14 days) was found to be associated with a 19% increase of risk of hospital admission for heart failure (adjusted odds ratio 1.19; 95% confidence interval 1.17 to 1.22), compared with past use of any NSAIDs (use >183 days in the past). Risk of admission for heart failure increased for seven traditional NSAIDs (diclofenac, ibuprofen, indomethacin, ketorolac, naproxen, nimesulide, and piroxicam) and two COX 2 inhibitors (etoricoxib and rofecoxib). Odds ratios ranged from 1.16 (95% confidence interval 1.07 to 1.27) for naproxen to 1.83 (1.66 to 2.02) for ketorolac. Risk of heart failure doubled for diclofenac, etoricoxib, indomethacin, piroxicam, and rofecoxib used at very high doses (≥2 defined daily dose equivalents), although some confidence intervals were wide. Even medium doses (0.9-1.2 defined daily dose equivalents) of indomethacin and etoricoxib were associated with increased risk. There was no evidence that celecoxib increased the risk of admission for heart failure at commonly used doses. CONCLUSIONS: The risk of hospital admission for heart failure associated with current use of NSAIDs appears to vary between individual NSAIDs, and this effect is dose dependent. This risk is associated with the use of a large number of individual NSAIDs reported by this study, which could help to inform both clinicians and health regulators.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Hosmer, D. W., & Lemeshow, S. (2000) · doi:10.1002/0471722146 · Cited by 20,302
Correspondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
Kearney, P. M., Baigent, C., Godwin, J., Halls, H., Emberson, J. R., & Patrono, C. (2006) · BMJ · doi:10.1136/bmj.332.7553.1302 · Cited by 1,445
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis
Trelle, S., Reichenbach, S., Wandel, S., Hildebrand, P., Tschannen, B., Villiger, P. M., Egger, M., & Juni, P. (2011) · BMJ · doi:10.1136/bmj.c7086 · Cited by 1,166
Adjusted P-Values for Simultaneous Inference
Wright, S. P. (1992) · Biometrics · doi:10.2307/2532694 · Cited by 1,026
BIAS DUE TO MISCLASSIFICATION IN THE ESTIMATION OF RELATIVE RISK
COPELAND, K. T., CHECKOWAY, H., McMICHAEL, A. J., & HOLBROOK, R. H. (1977) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112408 · Cited by 1,000
Schneeweiss, S. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1200 · Cited by 727
McGettigan, P., & Henry, D. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001098 · Cited by 571
Mamdani, M., Juurlink, D. N., Lee, D. S., Rochon, P. A., Kopp, A., Naglie, G., Austin, P. C., Laupacis, A., & Stukel, T. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16299-5 · Cited by 435
Proper interpretation of non-differential misclassification effects: expectations vs observations
Jurek, A. M., Greenland, S., Maldonado, G., & Church, T. R. (2005) · International Journal of Epidemiology · doi:10.1093/ije/dyi060 · Cited by 410
Bias in the Coding of Hospital Discharge Data and Its Implications for Quality Assessment
Romano, P. S., & Mark, D. H. (1994) · Medical Care · doi:10.1097/00005650-199401000-00006 · Cited by 346
Cooper, H., & Patall, E. A. (2009) · Psychological Methods · doi:10.1037/a0015565 · Cited by 339
García Rodríguez, L. A., Tacconelli, S., & Patrignani, P. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.041 · Cited by 305
A systematic review of validated methods for identifying heart failure using administrative data
Saczynski, J. S., Andrade, S. E., Harrold, L. R., Tjia, J., Cutrona, S. L., Dodd, K. S., Goldberg, R. J., & Gurwitz, J. H. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2313 · Cited by 278
A literature review of the epidemiology and treatment of acute gout
Kim, K. Y., Ralph Schumacher, H., Hunsche, E., Wertheimer, A. I., & Kong, S. X. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80158-3 · Cited by 274
Altman, D. G., & Bland, J. M. (2007) · BMJ · doi:10.1136/bmj.38977.682025.2c · Cited by 196
Epidemiology of gout: An update
Smith, E. U. R., Díaz-Torné, C., Perez-Ruiz, F., & March, L. M. (2010) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2010.10.004 · Cited by 186
Bernatsky, S., Hudson, M., & Suissa, S. (2005) · Rheumatology · doi:10.1093/rheumatology/keh610 · Cited by 154
Nonsteroidal Anti-Inflammatory Drugs and Heart Failure
Bleumink, G. S., Feenstra, J., Sturkenboom, M., & Stricker, B. H. C. (2003) · Drugs · doi:10.2165/00003495-200363060-00001 · Cited by 147
Self-citationNonsteroidal Anti-Inflammatory Drugs and the Heart
Patrono, C., & Baigent, C. (2014) · Circulation · doi:10.1161/circulationaha.113.004480 · Cited by 139
Nonsteroidal Antiinflammatory Drugs as a Trigger of Clinical Heart Failure
Rodríguez, L. A. G., & Hernández–Dı́az, S. (2003) · Epidemiology · doi:10.1097/01.ede.0000034633.74133.c3 · Cited by 138
Trifirò, G., Coloma, P. M., Rijnbeek, P. R., Romio, S., Mosseveld, M., Weibel, D. M., Bonhoeffer, J., Schuemie, M. J., van der Lei, J., & Sturkenboom, M. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12159 · Cited by 132
Self-citationBurden of New Hospitalization for Heart Failure: A Population-Based Investigation from Italy
Corrao, G., Ghirardi, A., Ibrahim, B., Merlino, L. G., & Maggioni, A. P. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.105 · Cited by 116
Self-citationAmer, M., Bead, V. R., Bathon, J. M., Blumenthal, R. S., & Edwards, D. N. (2010) · Cardiology in Review · doi:10.1097/crd.0b013e3181ce1521 · Cited by 113
Koffeman, A. R., Valkhoff, V. E., Çelik, S., Jong, G. W. ‘., Sturkenboom, M., Bindels, P., van der Lei, J., Luijsterburg, P. A. J., & Bierma‐Zeinstra, S. (2014) · British Journal of General Practice · doi:10.3399/bjgp14x677815 · Cited by 105
Self-citationUsing prescription claims data for drugs available over‐the‐counter (OTC)
Yood, M. U., Campbell, U. B., Rothman, K. J., Jick, S. S., Lang, J. M., Wells, K. E., Jick, H., & Johnson, C. C. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1454 · Cited by 102
Huerta, C., Varas‐Lorenzo, C., Castellsagué, J., & Rodriguez, L. A. G. (2006) · Heart · doi:10.1136/hrt.2005.082388 · Cited by 102
Self-citationGout and the risk for incident heart failure and systolic dysfunction
Krishnan, E. (2012) · BMJ Open · doi:10.1136/bmjopen-2011-000282 · Cited by 101
Bäck, M., Yin, L., & Ingelsson, E. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr421 · Cited by 92
Avillach, P., Coloma, P. M., Gini, R., Schuemie, M. J., Fleur Mougin, A., Dufour, J.-C., Mazzaglia, G., Giaquinto, C., Fornari, C., Herings, R. M. C., et al. (2012) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2012-000933 · Cited by 89
Self-citationScott, P. A., Kingsley, G. H., & Scott, D. L. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.07.013 · Cited by 82
Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice?
Howes, L. G. (2007) · PubMed Central · Cited by 80
Duong, M., Salvo, F., Pariente, A., Abouelfath, A., Lassalle, R., Droz‐Perroteau, C., Blin, P., & Moore, N. D. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12239 · Cited by 71
Self-citationNonsteroidal Anti-Inflammatory Drugs and the Heart
CarloPatrono, & ColinBaigent (2014) · Circulation · Cited by 71
Mangoni, A. A., Woodman, R. J., Gaganis, V., Gilbert, A. L., & Knights, K. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03627.x · Cited by 52
Valkhoff, V. E., Schade, R., Jong, G. W. ‘., Romio, S., Schuemie, M. J., Arfè, A., Garbe, E., Herings, R. M. C., Lucchi, S. R., Picelli, G., et al. (2013) · BMC Pediatrics · doi:10.1186/1471-2431-13-192 · Cited by 52
Self-citationMcGettigan, P., Han, P., Jones, L., Whitaker, D., & Henry, D. A. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03121.x · Cited by 36
Moride, Y., Ducruet, T., Boivin, J., Moore, N. D., Perreault, S., & Zhao, S. Z. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1488 · Cited by 29
Lui, K. (1988) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114882 · Cited by 18
Fabule, J., & Adebajo, A. (2014) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x14541668 · Cited by 17
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Authors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2333 · Cited by 2,171
Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective
Bindu, S., Mazumder, S., & Bandyopadhyay, U. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114147 · Cited by 1,920
Cardiovascular effects and safety of (non-aspirin) NSAIDs
Schjerning, A.-M., McGettigan, P., & Gislason, G. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0366-z · Cited by 387
Metadata
- Authors
- Arfè, A., Scotti, L., Varas-Lorenzo, C., Nicotra, F., Zambon, A., Kollhorst, B., Schink, T., Garbe, E., Herings, R., Straatman, H., Schade, R., Villa, M., Lucchi, S., Valkhoff, V., Romio, S., Thiessard, F., Schuemie, M., Pariente, A., Sturkenboom, M., & Corrao, G.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2016-09-28
- Volume
- 354
- Pages
- i4857
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W2527335739
- Cited by
- 290
- References
- 50
- FWCI
- 21.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.